Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.45M | 13.28M | 12.59M | 12.09M | 16.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.45M | 13.28M | 12.59M | 12.09M | 16.59M |
| Cost of Revenue | 69.66M | 67.22M | 55.48M | 48.92M | 50.01M |
| Gross Profit | -51.21M | -53.94M | -42.89M | -36.83M | -33.42M |
| SG&A Expenses | 11.65M | 10.72M | 11.72M | 11.71M | 11.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.32M | 77.94M | 67.20M | 60.63M | 61.80M |
| Operating Income | -62.86M | -64.66M | -54.61M | -48.54M | -45.22M |
| Income Before Tax | -56.35M | -58.54M | -48.87M | -44.46M | -41.43M |
| Income Tax Expenses | -- | 8.00K | 82.00K | 90.00K | 90.00K |
| Earnings from Continuing Operations | -56.35M | -58.55M | -48.96M | -44.55M | -41.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.35M | -58.55M | -48.96M | -44.55M | -41.52M |
| EBIT | -62.86M | -64.66M | -54.61M | -48.54M | -45.22M |
| EBITDA | -60.51M | -63.41M | -52.22M | -46.21M | -43.17M |
| EPS Basic | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 |
| Normalized Basic EPS | -0.42 | -0.47 | -0.42 | -0.45 | -0.47 |
| EPS Diluted | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 |
| Normalized Diluted EPS | -0.42 | -0.47 | -0.42 | -0.45 | -0.47 |
| Average Basic Shares Outstanding | 83.56M | 78.41M | 72.78M | 62.38M | 54.90M |
| Average Diluted Shares Outstanding | 83.56M | 78.41M | 72.78M | 62.38M | 54.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |